Serum testosterone level as possible predictive marker in androgen receptor axis-targeting agents and taxane chemotherapies for castration-resistant prostate cancer
Currently, several therapeutic options for castration-resistant prostate cancer (CRPC) are available, for which predictive biomarkers have not been established. Therefore, we aimed to reveal the association between pretreatment serum testosterone level and antitumor outcomes when treated with androgen receptor axis-targeting agents and taxane chemotherapies for CRPC.
Source: Urologic Oncology: Seminars and Original Investigations - Category: Urology & Nephrology Authors: Masaki Shiota, Eiji Kashiwagi, Tomohiko Murakami, Ario Takeuchi, Kenjiro Imada, Junichi Inokuchi, Katsunori Tatsugami, Masatoshi Eto Tags: Original Article Source Type: research